About Us

Innaxon Therapeutics is an early stage development company based at in Bristol, United Kingdom. Innaxon's in-house biopharmaceuticals Toll-like Receptor 4 (TLR4) agonists (Dendrophilin® Novo-Pyrexal®) and in-licensed small molecule inhibitors (IAXOTM compounds) have been shown in proof-of-concept pre-clinical studies to treat cancer and prevent serious inflammatory diseases, respectively.

IAXO Small Molecules


IAXO compounds are Glycolipids and Benzylammonium Lipids designed to act as Lipid A analogues that hold considerable promise in pharmacological settings, where inhibition of sterile (auto-) inflammation is desired, without compromising TLR4’s key role in the defense of pathogens. CD14-dependent and independent TLR4 activation of immune and non-immune cells by endogenous factors has been recently shown in a proof of concept preclinical study for inflammatory diseases such as abdominal aortic aneurysm (AAA).